Table 2.

Response to treatment with ruxolitinib

Parameter	aGVHD, n = 10	cGVHD, n = 28
Overall response rate, n (%)	10 (100)	22 (82.1)
Median follow-up time in mo, median (range)	2.5 (1.5–4)	5 (1.5–10)
Time to best overall response in mo, median (range)	1.0 (0.5–2.5)	3.0 (1.0–9.5)
Time to best response for each organ system in d, median (range)
Skin	28 (14–28)	77 (7–147)
Digestive tract	25 (14–60)	259 (70–308)
Liver	32 (21–42)	42 (28–56)
Eye	-	112 (42–182)
Oral cavity	-	80 (28–168)
Lung	-	91 (49–140)
Fascia	-	91 (56–266)
Discontinuation of immunosuppressive agents after ruxolitinib, n (%)	8 (80.0)	21 (75.0)

aGVHD: Acute graft-vs-host disease; cGVHD: Chronic graft-vs-host disease.